Danaher Corporation research snapshot
DHR AI stock analysis currently reads Danaher Corporation as a high-quality life sciences, biotechnology, and diagnostics platform where the Danaher Business System, recurring consumables, regulated workflows, and acquisition discipline support long-term value creation. At the July 8, 2026 data cutoff, DHR traded near $194.19 with a verified market capitalization near $137.4 billion. The main offset is that the post-pandemic life sciences recovery is still uneven, Diagnostics is absorbing lower respiratory revenue, the planned Masimo acquisition adds execution risk, and valuation still assumes a return to steady earnings growth. This page uses scenario ranges and source-backed checks, not a certain price prediction, and is for informational use only.
Current price
$194.19
Market cap
$137.4 billion
AI score
72 / 100
Rating
High-quality life sciences and diagnostics platform, recovery still being tested
Trend status
Constructive short-term momentum, with mixed 200-day moving average signals across data providers
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Danaher sells mission-critical biotechnology, life sciences, and diagnostics tools into regulated research, manufacturing, and clinical workflows with recurring consumables and service demand. | High |
| Moat | Moat comes from installed instruments, consumables pull-through, workflow switching costs, regulatory know-how, scale, proprietary technology, and the Danaher Business System operating model. | High |
| Management | Management has a long record of portfolio shaping and cash discipline, but the Masimo acquisition plan and the next life sciences cycle will test capital allocation quality. | Medium-high |
| Financial trend | FY2025 revenue rose 3.0% to $24.568 billion and non-GAAP free cash flow was $5.3 billion. Q1 2026 revenue rose 3.5% to $5.951 billion, but non-GAAP core revenue growth was only 0.5%. | High |
| Valuation | At $194.19 and the $8.45 midpoint of 2026 adjusted EPS guidance, DHR traded near 23.0x forward adjusted EPS, 2.6x book value, 25.9x FY2025 free cash flow per share, and 5.6x sales. | Medium-high |
| Technical trend | DHR is above several short-term moving averages, but 200-day readings differ by provider, with Investing.com near $184.52 and Barchart near $204.01. | Medium |
| Risk level | Key risks include slower bioprocessing recovery, weak instruments demand, China policy headwinds, Diagnostics respiratory normalization, Masimo integration, leverage after acquisitions, and multiple compression. | Medium-high |
| AI confidence | High for descriptive facts and audited math. Lower for price outcomes because the equity is sensitive to growth recovery and terminal multiple assumptions. | High data confidence |
| Investment certainty | Medium certainty. DHR is a quality business, but the page gives a research framework and scenario ranges, not a buy or sell instruction. | Medium |
DHR AI stock forecast
The DHR AI stock forecast uses scenario math around the $194.19 quote and the $8.45 midpoint of Danaher updated 2026 adjusted diluted EPS guidance. The audited three-year framework produced a bearish area near $135, a base area near $221, and a bullish area near $281 before dividends. The range is wide because Danaher combines high business quality with a cyclical life sciences recovery and acquisition execution risk.
$265 to $290
More likely if Biotechnology core growth keeps improving, bioprocessing demand returns to high single-digit growth, Life Sciences stabilizes, Diagnostics non-respiratory growth offsets lower respiratory revenue, Masimo integration is disciplined, and the market values DHR near 25x earnings.
$210 to $230
More likely if adjusted EPS compounds around the mid single digits, 2026 guidance is met, free cash flow conversion remains high, and DHR trades around 22x earnings.
$130 to $145
More likely if bioprocessing recovery disappoints, Life Sciences instruments stay weak, China policy headwinds grow, Masimo adds debt or distraction, and investors compress DHR toward a mid-to-high teens earnings multiple.
DHR AI technical analysis
DHR AI technical analysis is constructive but not clean as of the July 8, 2026 data cutoff. Price was near $194, above short-term trend gauges and close to the 50-day moving average in some data sets, while 200-day moving average snapshots differed enough to treat the long-term trend as a test rather than a confirmed breakout.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $194.19 | Danaher investor relations quote snapshot showed $194.19 and a $137.4 billion market cap around the July 8, 2026 cutoff. |
| Near support | $186 to $194 | Barchart listed the 20-day moving average near $186.60 and Investing.com listed the 5-day and 50-day moving averages near $193.5. |
| Deeper support | $160.93 to $179 | The company quote page listed a 52-week low of $160.93, while Barchart placed the 50-day moving average near $179.18. |
| Near resistance | $198 to $204 | Recent trading around $197 to $198 and Barchart 200-day moving average near $204 form the first resistance band. |
| Long-term resistance | $225 to $243 | This zone covers prior rebound supply and the 52-week high of $242.80 reported by Danaher investor relations and MarketWatch. |
| Moving averages | 50-day near $179 to $194, 200-day near $185 to $204 | Provider differences mean the signal should be refreshed before trading, but the stock was no longer deeply below every moving average. |
| Momentum | RSI roughly 52 to 60 | Investing.com and Barchart snapshots showed neutral to firm RSI readings, not an extreme overbought or oversold condition. |
| Volume | Average volume near 4.2 million to 4.8 million shares | Barchart and MarketWatch snapshots put recent average volume in this range, useful for judging breakout quality. |
| Volatility | $160.93 to $242.80 52-week range | The wide range shows that life sciences demand, earnings, acquisition news, and rates can materially reset the stock. |
| Invalidation | Close below $186, then $179 | A decisive close below the 20-day area would weaken the recovery setup. A break below the 50-day area would imply a failed intermediate trend. |
DHR AI trading strategy
The DHR AI trading strategy is a rules-based framework for monitoring a life sciences quality stock after a long reset. It is not personal advice and should be paired with live chart data, filings, position sizing, and defined invalidation levels.
Watch for DHR to hold above the $186 to $194 support band and reclaim the $198 to $204 resistance zone on volume above recent averages. Confirmation improves if Q2 results show Biotechnology and Life Sciences demand improving without margin slippage.
A close below $186, or a failed breakout after weaker core growth guidance, should invalidate the near-term trend setup.
If DHR pulls back toward the $179 to $186 zone without new balance sheet, guidance, or demand damage, compare price action with 2026 adjusted EPS guidance, free cash flow conversion, China headwinds, and Masimo transaction updates.
Do not average down without a maximum loss rule because healthcare tools stocks can gap lower when end-market demand or acquisition confidence changes.
Track core revenue growth by segment, Bioprocessing orders, Life Sciences instruments demand, Diagnostics respiratory revenue, Cepheid trends, China policy impact, adjusted operating margin, free cash flow, net debt, and Masimo integration commentary.
Reduce confidence if EPS growth depends mainly on cost actions or multiple expansion while organic growth and free cash flow conversion weaken.
Investment research summary
Danaher helps biopharma, research, industrial, and clinical customers develop therapies, run labs, manufacture biologics, and diagnose disease. Customers pay because these workflows are regulated, time-sensitive, and costly to rebuild internally.
The moat is built from installed systems, consumables, workflow know-how, service networks, regulatory familiarity, scale, technology, and operating discipline. It weakens if customers delay instruments, competitors lower consumables pricing, or new methods reduce the need for current workflows.
The thesis fails if bioprocessing demand does not recover, China headwinds persist, Diagnostics loses higher-margin respiratory revenue faster than expected, Masimo distracts management, or acquisition goodwill and intangibles prove too optimistic.
Rainer Blair and Danahers operating system provide continuity, but investors should judge management by organic growth recovery, acquisition discipline, integration quality, cash conversion, and willingness to protect long-term innovation over short-term EPS optics.
Danaher sits inside long-duration demand for biologic drugs, diagnostics, clinical testing, lab automation, and life sciences productivity. The counterweight is that customer budget cycles and post-pandemic inventory normalization can delay growth.
At roughly 23x 2026 adjusted EPS guidance, the market prices DHR as a quality recovery story rather than a distressed healthcare tools stock. Margin of safety depends on real core growth, free cash flow durability, and disciplined use of the balance sheet.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DHR price | $194.19 quote snapshot | Danaher investor relations stock quote | July 8, 2026 |
| Market capitalization | $137.4 billion, verified as $194.19 x 707.77 million shares with 0.03% variance | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 707.77 million shares in a current third-party quote snapshot, with 711.2 million diluted shares used in Q1 2026 EPS math | Morningstar quote and Danaher Q1 2026 results | July 8, 2026 |
| FY2025 revenue | $24.568 billion, cross-validated against Danaher, Macrotrends, and StockAnalysis with 0.00% variance | Danaher FY2025 results release | July 8, 2026 |
| FY2025 net earnings | $3.614 billion total net earnings, cross-validated against Danaher and StockAnalysis with rounded third-party variance of 0.39% | Danaher FY2025 results release | July 8, 2026 |
| FY2025 free cash flow | $5.3 billion non-GAAP free cash flow | Danaher FY2025 results release | July 8, 2026 |
| Q1 2026 revenue and EPS | $5.951 billion sales, $1.029 billion net earnings, $1.45 GAAP diluted EPS, and $2.06 adjusted diluted EPS | Danaher Q1 2026 results release | July 8, 2026 |
| 2026 adjusted EPS guidance | $8.35 to $8.55, raised after Q1 2026 results; midpoint $8.45 used for scenario math | Danaher Q1 2026 results release | July 8, 2026 |
| Segment core growth outlook | FY2026 core growth expected at 3% to 6%, with Biotechnology near +6%, Life Sciences up slightly, and Diagnostics low single digit | Danaher Q1 2026 earnings supplement | July 8, 2026 |
| Cash and debt | StockAnalysis listed $5.70 billion cash and $19.68 billion debt MRQ; FY2025 company release listed $4.742 billion cash and $18.418 billion debt, so timing differences are material | StockAnalysis statistics and Danaher FY2025 balance sheet | July 8, 2026 |
| Technical snapshot | Investing.com RSI 52.0, 50-day MA $193.57, 200-day MA $184.52; Barchart RSI near 60, 50-day MA $179.18, 200-day MA $204.01 | Investing.com and Barchart technical snapshots | July 8, 2026 |
| Three-scenario valuation | financial_rigor.py output: bullish $281.2, base $221.4, bearish $135.2 using $8.45 EPS, 10% / 6% / -2% growth and 25x / 22x / 17x PE | financial_rigor.py three-scenario calculation | July 8, 2026 |
This DHR AI stock analysis is an informational research tool only and is not investment advice, financial planning, or a recommendation to buy, sell, or hold Danaher Corporation. Forecast ranges are scenarios based on available data as of July 8, 2026, and can be wrong if earnings, demand, rates, acquisition terms, regulation, or market multiples change.
